Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208761
Title: | TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck |
Author: | Mesía, Ricard Rubió-Casadevall, Jordi Cirauqui Cirauqui, Beatriz Martinez Trufero, Javier Plana Serrahima, Maria García Castaño, Almudena Carral Maseda, Alberto Iglesias Docampo, Lara Pérez Segura, Pedro Ceballos Lenza, Isaac Gutiérrez Calderón, Vanesa Fuster Salvà, José Pena Álvarez, Carolina Hernandez, Irene Barco Morillo, Edel del Chaves Conde, Manuel Martínez Galán, Joaquina Durán Sánchez, Marisa Quiroga Garcia, Vanesa Ortega, Eugenia |
Keywords: | Malalts hospitalitzats Càncer de cap Càncer de coll Anticossos monoclonals Hospital patients Head cancer Neck cancer Monoclonal antibodies |
Issue Date: | 1-Aug-2023 |
Publisher: | Frontiers Media |
Abstract: | Objectives: The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy. Materials and methods: This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high accumulated dose of PT, or PT refractoriness. Results: A total of 531 patients from 16 hospitals in Spain were enrolled. The median age was 66 years, 82.7% were male, and 83.5% were current/former smokers. Patients were ineligible to receive PT due to ECOG 2 (50.3%), comorbidities (32%), PT cumulative dose ≥ 225 mg/m2 (10.5%), or PT refractoriness (7.2%). Response rate was 37.7%. Median duration of response was 5.6 months (95% CI: 4.4-6.6). With a median follow-up of 8.7 months (95% CI: 7.7-10.2), median PFS and OS were 4.5 months (95% CI: 3.9-5.0) and 8.9 months (95% CI: 7.8-10.3), respectively. Patients treated with immunotherapy after ERBITAX had better OS with a median of 29.8 months compared to 13.8 months for those who received other treatments. The most common grade ≥ 3 toxicities were acne-like rash in 36 patients (6.8%) and oral mucositis in 8 patients (1.5%). Five (0.9%) patients experienced grade ≥ 3 febrile neutropenia. Conclusion: This study confirms the real-world efficacy and tolerability of ERBITAX as first-line treatment in recurrent/metastatic SCCHN when PT is not feasible. Immunotherapy after treatment with ERBITAX showed remarkable promising survival, despite potential selection bias. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2023.1226939 |
It is part of: | Frontiers In Oncology, 2023, vol. 13 |
URI: | http://hdl.handle.net/2445/208761 |
Related resource: | https://doi.org/10.3389/fonc.2023.1226939 |
ISSN: | 2234-943X |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
827631.pdf | 4.86 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License